Clinical Trial VICCBRE1304


A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases

Principal Investigator(s)

Vandana Abramson


  • Protocol No. VICCBRE1304
  • Open Date: 06/04/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the intracranial objective response rate of mTOR inhibition (everolimus) in combination with vinorelbine and trastuzumab in the treatment of HER2-positive progressive breast cancer brain metastases as defined via modified RECIST criteria
  • Disease Sites: Breast
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Everolimus (RAD001); Herceptin; Trastuzumab (Herceptin); Vinorelbine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01305941
  • Secondary Protocol No: LCCC1025



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.